Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Fisher & Paykel Healthcare Corporation Limited ( (NZ:FPH) ).
Fisher & Paykel Healthcare has disclosed that The Vanguard Group, Inc. has become a substantial product holder in the company, accumulating 29,373,095 ordinary shares, equivalent to 5.001% of its quoted voting stock. The holding arose from a series of buy and sell transactions executed between mid-January and early March 2026 across both NZD and AUD markets, reflecting increasing institutional interest in the stock and potentially enhancing the company’s profile among global investors.
The declaration of Vanguard’s position signals a vote of confidence from one of the world’s largest asset managers and may support liquidity and stability in Fisher & Paykel Healthcare’s share register. While the notice itself does not alter operations, a larger long-term institutional presence can influence market perception, governance engagement, and the breadth of the company’s international shareholder base.
The most recent analyst rating on (NZ:FPH) stock is a Hold with a N$39.50 price target. To see the full list of analyst forecasts on Fisher & Paykel Healthcare Corporation Limited stock, see the NZ:FPH Stock Forecast page.
More about Fisher & Paykel Healthcare Corporation Limited
Fisher & Paykel Healthcare Corporation Limited is a medical technology company that designs and manufactures products for respiratory care, intensive care, and sleep apnea treatment. The New Zealand-based firm focuses on hospital and home healthcare markets, supplying breathing systems, humidification devices, and related equipment globally.
Average Trading Volume: 506,436
Technical Sentiment Signal: Hold
Current Market Cap: N$19.02B
Find detailed analytics on FPH stock on TipRanks’ Stock Analysis page.